An Update on the PDE-5 Inhibitors (PDE-5i)

Journal of Andrology

Volumn 24, Issue 6 SUPPL., 2003, Pages

  McCullough, Andrew R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYCLIC GMP; NITRATE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

BACKACHE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; IMPOTENCE; MALE; MYALGIA; PENIS ERECTION; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; VISUAL DISORDER;

EID: 0242625934     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1939-4640.2003.tb02747.x     Document Type: Conference Paper

References (12)

1. Baxendale RW, et al. Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against human phosphodiesterase types 7-11. J Clin Pharmacol. 2001;41:1015.
2. Baxendale RW, Phillips SC. Human PDE-11: a distinct,dual substrate phosphodiesterase expressed in vascular smooth muscle and cardiac myocytes. Circulation. 2000;102:320.
3. Beavo JA. Cyclic nucleotide phosphodiesterases:functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
4. Corbin JD, Francis SH. Pharmacology of phophodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453-459.
5. Eardley I. Sexual habits in the UK. Int J Imp Res. 2002;14.
6. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001;65:1-52.
7. Hellstrom W, Overstreet JW, Yu A, Shen W, Beasley CM, Watkins VS. Tadalfi has no effect on spermatogenesis or reproductive hormones. J Urol. 2003;170:887-891.
8. Hellstrom WJ, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003;61:8-14.
9. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.
10. Montorsi F, Verheyden B, Junemann KP, Moncado I, Valiquette L, Denne J, Watkins VS. Long-term safety experience with tadalafil. J Urol. 2003;169:244.
11. Nichols DJ, Muirhead GJ, Harness JA. Pharmakokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53:5S-12S.
12. Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C-44C.